Interneuron: Rehabilitation

Through a flurry of deals at year end, Interneuron Pharmaceuticals Inc. is working to rehabilitate its original business model of in-licensing products, adding value through clinical trials and regulatory milestones and then out-licensing the products to new partners.

However, the company has yet to demonstrate that the model works.

Read the full 494 word article

How to gain access

Continue reading with a
two-week free trial.